dc.contributor | Consorci Sanitari de Terrassa |
dc.contributor.author | Chatzikonstantinou, Thomas |
dc.contributor.author | Kapetanakis, Anargyros |
dc.contributor.author | Scarfo', Lydia |
dc.contributor.author | Allsup, David |
dc.contributor.author | Cabrero, Alejandro Alonso |
dc.contributor.author | Cuéllar-García, C. |
dc.contributor.author | KARAKATSOULIS, GEORGIOS |
dc.date.accessioned | 2023-09-22T10:57:45Z |
dc.date.available | 2023-09-22T10:57:45Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Chatzikonstantinou T, Karakatsoulis G, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia. 2021 Dec;35(12):3444-54. |
dc.identifier.uri | https://hdl.handle.net/11351/10343 |
dc.description | Chronic lymphocytic leukemia; Coronavirus infections; Mortality |
dc.description.abstract | Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Leukemia;35(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Leucèmia limfoide |
dc.subject | Mortalitat |
dc.subject | COVID-19 (Malaltia) |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Leukemia, Lymphoid |
dc.subject.mesh | Mortality |
dc.title | COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41375-021-01450-8 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | leucemia linfoide |
dc.subject.decs | mortalidad |
dc.relation.publishversion | https://doi.org/10.1038/s41375-021-01450-8 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Chatzikonstantinou T] Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. [Kapetanakis A] Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. [Scarfò L] Università Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy. [Karakatsoulis G] Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. Department of Mathematics, University of Ioannina, Ioannina, Greece. [Allsup D] Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, Hull, UK. [Cabrero AA] Spanish Society of Haematology and hemotherapy, Madrid, Spain. Hematology Department, Hospital Universitario de La Princesa, Madrid, Spain. [Cuéllar-García C] Unitat d'Hematologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain |
dc.identifier.pmid | 34725454 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |